Retirzepatide 35mg Retatrutide + Tirzepatide

Retirzepatide is a research blend containing 20mg retatrutide and 15mg tirzepatide. Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1 and glucagon receptors, while tirzepatide is a GIP/GLP-1 receptor agonist. Both compounds are being studied in metabolic and obesity-related research. 

Research areas include: metabolic research, glucose and insulin signalling, body-weight regulation, appetite-related pathways and cardiometabolic health. Clinical studies have evaluated retatrutide and tirzepatide separately, but the specific 20mg retatrutide + 15mg tirzepatide combination shown here has not been established as an approved or clinically validated combination treatment. 

Important: Retatrutide remains investigational and is not approved for general human use. The specific Retirzepatide blend and self-mix formulation shown here should not be represented as an approved treatment. This product is provided for research purposes only and is not intended to diagnose, treat, cure or prevent any disease or medical condition.

The Certificate of Analysis for lot GX-2026 confirms an HPLC purity of 99%+ and identity confirmed by mass spectrometry.

The Safety Data Sheet describes handling, storage and disposal information for this research compound. Always follow standard laboratory safety practice.